Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Jan

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Opening Session Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Adjuvant Durvalumab in Resected Early-Stage NSCLC

Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25

AACR Announces Fellows of the AACR Academy Class of 2026

Extended Endocrine Therapy in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer

Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett Esophagus Esophageal Cancer